For Immediate Release
Douglas Flora, MD Appointed Editor-in-Chief of New Journal AI in Precision Oncology
Contact: Kathryn Ryan
914-740-2250
kryan@liebertpub.com
New Rochelle, NY, June 21, 2023—Mary Ann Liebert, Inc. announces the launch of AI in Precision Oncology, the only academic, bimonthly peer-reviewed research journal dedicated to the advancement of artificial intelligence applications in clinical and precision oncology. The Journal will publish a preview issue in Fall 2023 and its inaugural issue in early 2024.
Aiming to support this burgeoning community of innovative researchers, practitioners, policy makers, and activists, AI in Precision Oncology will centralize essential research, reviews, information, and analysis on this revolutionary technology within a single reputable and trusted resource. The Journal’s mission is to amplify the benefits of integrative artificial intelligence technology within cancer detection, diagnosis, and prognosis to improve patient lives and outcomes, and much more.
Spearheaded by Editor-in-Chief Douglas Flora, MD, Executive Medical Director, Oncology Services, St. Elizabeth, and supported by a diverse and accomplished team of experts, including David Penberthy, MD, MBA, Associate Professor of Radiation Oncology, Penn State Health; Nikhil Thaker, MD, Chief Medical Informatics Officer, Arizona Oncology; and Scott Penberthy, Managing Director of AI at Google, the Journal provides a high-profile forum for cutting-edge research, reviews, and frontmatter highlighting important advances in this rapidly developing field. Editorial Board Members include Leroy (Lee) Hood, MD, PhD, Institute for Systems Biology, Teri Klein, PhD, Stanford University, Nihal El Rouby, PhD, University of Cincinnati, Jill Kolesar, PhD, University of Kentucky, and many more.
“As the Editor-in-Chief of AI in Precision Oncology, I believe our journal will be instrumental in advancing the field by fostering collaboration, disseminating groundbreaking research, and catalyzing the translation of AI into clinical applications,” says Dr. Douglas Flora. “Together, we will revolutionize cancer care and improve patient outcomes through the power of artificial intelligence. This journal will provide clinicians, researchers, and decision-makers the tools they need to make meaningful decisions for the future of positive patient outcomes and patient care in oncology.”
AI in Precision Oncology invites submissions on a wide range of topics related to AI in precision oncology, including but not limited to:
- AI algorithms for cancer detection, diagnosis, and prognosis
- AI-based biomarkers for cancer screening and diagnosis
- AI-assisted imaging analysis for tumor detection and segmentation
- AI-guided treatment planning and personalized therapy
- AI-enabled drug discovery and development
- Machine learning and deep learning in cancer research
- Natural language processing for electronic health record analysis
- Ethical and regulatory issues in AI in Oncology
We encourage the submission of original research articles, systematic reviews, meta-analyses, and perspectives on the use of AI in precision oncology. Our journal also accepts letters to the editor and commentaries on current issues in the field. Our editorial team consists of experts in the field of AI in oncology who have a broad range of expertise and experience in academia, industry, and clinical practice and ensures that all submissions undergo rigorous peer review by experts in the field to ensure the highest standards of scientific rigor and transparency. Pre-submission inquiries are currently welcome.
The use of AI in oncology has the potential to revolutionize cancer care, from early detection to precision medicine. AI can assist in analyzing complex data, such as genomics, imaging, and electronic health records, to improve cancer diagnosis and treatment planning. Moreover, AI can help predict treatment responses, identify new drug targets, and facilitate clinical trials. The Journal's scope includes all aspects of AI in oncology, from basic research to clinical implementation.
As a peer-reviewed forum, the Journal aims to help professionals in the field of oncology understand how artificial intelligence and technology solutions can be applied in an evidence-based, ethical, and thoughtful manner. Overall, the Journal seeks to promote AI's responsible and effective use in oncology, benefiting both healthcare providers and patients. Our shared goal is to use this forum to help develop care for cancer patients that is safer, easier, and ultimately more human.
To sign up for future email alerts for AI in Precision Oncology, click here.
About the Publisher
Mary Ann Liebert, Inc. is a global media company dedicated to creating, curating, and delivering impactful peer-reviewed research and authoritative content services to advance the fields of biotechnology and the life sciences, specialized clinical medicine, public health and policy, and technology and engineering. For complete information, please visit the Mary Ann Liebert, Inc. website.